{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"title":"partial response"},{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"3"}],"title":"stable disease"},{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"7"}],"title":"progressive disease"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"}],"title":"not evaluable for response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"11"}],"units":"Participants"}],"description":"Response rates will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST):\n\nComplete Response (CR) - Disappearance of all target lesions Partial Response (PR) - ≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline Progressive Disease (PD) - ≥20% increase in the sum of the longest diameter of the target lesions compared with the smallest sum of the longest diameter recorded since treatment started OR The appearance of 1 or more new lesions Stable Disease (SD) - Neither PR or PD Not Evaluable (NE)","groups":[{"description":"Metastatic breast cancer\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"OG000","title":"Arm 1"},{"description":"Metastatic colorectal cancer that harbors the Kras or BRAF mutation\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"OG001","title":"Arm 2"},{"description":"Advanced or metastatic esophageal and/or gastric cancer\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"OG002","title":"Arm 3"},{"description":"Cisplatin-refractory, unresectable germ cell tumors\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"OG003","title":"Arm 4"},{"description":"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.\n\nPD-0332991: Given orally, 125 mg QD on a 21-day","id":"OG004","title":"Arm 5"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"10 years","title":"Response Rates","type":"PRIMARY","unitOfMeasure":"Participants"}